Impact of 100 LRRK2 variants linked to Parkinson’s Disease on kinase activity and microtubule binding
Alexia F. Kalogeropulou(Foghorn Therapeutics (United States)), Dario R. Alessi(MRC Protein Phosphorylation and Ubiquitylation Unit), Melanie Wightman(University of Dundee), Alan R. Prescott(University of Dundee), Francesca Tonelli(University of Pavia), Shalini Padmanabhan(Michael J. Fox Foundation), Sven M. Lange(Harvard University), Esther Sammler(University of Dundee), Elena Purlyte(University of Dundee)
Cited by 8
Related Papers
Mechanism of activation of protein kinase B by insulin and IGF‐1.
|The EMBO Journal|1996|3k
Identification of pleckstrin-homology-domain-containing proteins with novel phosphoinositide-binding specificities
|Biochemical Journal|2000|518
The PI3K‒PDK1 connection: more than just a road to PKB
|Biochemical Journal|2000|501
14-3-3 binding to LRRK2 is disrupted by multiple Parkinson's disease-associated mutations and regulates cytoplasmic localization
|Biochemical Journal|2010|402
Rab29 activation of the Parkinson's disease‐associated LRRK2 kinase
|The EMBO Journal|2017|367